Novo Nordisk A/S (NYSE: NVO) sharply increased its U.S. advertising spend on its blockbuster GLP-1 drugs Wegovy and Ozempic in 2025, outpacing rival Eli Lilly and Co (NYSE: LLY) as competition for ...
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have a lot in common. They both have made significant breakthroughs in the market for diabetes medicine, a field in which they have been competing ...
Hosted on MSN
Eli Lilly just delivered great news for investors -- and it goes beyond weight-loss drugs
Eli Lilly's success rate in clinical trials was phenomenal last year. The drugmaker has made a big name for itself in diabetes and weight loss. But it's also proving innovative even beyond its core ...
Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results